Navidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.com
StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Wednesday. The firm issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of NYSE NAVB opened at $0.05 on Wednesday. Navidea Biopharmaceuticals has a twelve month low of $0.02 and a twelve month high […]
More Stories
Global X Clean Tech ETF (NASDAQ:CTEC) Sees Large Decrease in Short Interest
Global X Clean Tech ETF (NASDAQ:CTEC – Get Free Report) saw a significant decline in short interest in the month...
International Isotopes Inc. (OTCMKTS:INIS) Short Interest Down 94.5% in December
International Isotopes Inc. (OTCMKTS:INIS – Get Free Report) was the target of a significant drop in short interest in December....
Cochlear Limited (OTCMKTS:CHEOY) Sees Large Decrease in Short Interest
Cochlear Limited (OTCMKTS:CHEOY – Get Free Report) was the recipient of a significant drop in short interest during the month...
Insider Buying: Crescita Therapeutics Inc. (TSE:CTX) Director Acquires 86,000 Shares of Stock
Crescita Therapeutics Inc. (TSE:CTX – Get Free Report) Director Jose Darocha bought 86,000 shares of the company’s stock in a...
Presidio Property Trust, Inc. (NASDAQ:SQFT) Short Interest Update
Presidio Property Trust, Inc. (NASDAQ:SQFT – Get Free Report) was the recipient of a significant growth in short interest in...
Short Interest in iShares ESG MSCI USA Leaders ETF (NASDAQ:SUSL) Rises By 353.3%
iShares ESG MSCI USA Leaders ETF (NASDAQ:SUSL – Get Free Report) saw a significant increase in short interest in the...